Skip to Content

Bromocriptine Pregnancy and Breastfeeding Warnings

Bromocriptine is also known as: Cycloset, Parlodel

Bromocriptine Pregnancy Warnings

Bromocriptine has been assigned to pregnancy category B by the FDA. Animal studies have failed to reveal evidence of embryotoxicity, fetotoxicity, and teratogenicity. There are no controlled data in human pregnancy. The safety of bromocriptine administration during pregnancy has not been established. Bromocriptine is only recommended for use during pregnancy when benefit outweighs risk.

Postmarketing data were collected in 1276 pregnancies. Although in the majority of the cases bromocriptine therapy was discontinued within 8 weeks of pregnancy, 8 patients received a mean daily dose of 5.8 mg (range 1 mg to 40 mg) continuously throughout pregnancy. Of the 1276 pregnancies, there were 1088 full-term deliveries (4 stillborn), 145 spontaneous abortions (11.4%), and 28 induced abortions (2.2%). In addition, 12 extrauterine gravidities and 3 hydatidiform moles (twice in the same patient) caused early termination of pregnancy. In spite of these case results, no correlation has been established between the use of bromocriptine and birth defects. A 29-year-old Japanese woman gave birth to a normal healthy male baby weighing 2.98 Kg after bromocriptine treatment throughout the 34th week of gestation. Bromocriptine 5 mg orally daily was initiated after failing other drug therapies used for the treatment of a microadenoma in the anterior pituitary lobe that affected her ability to conceive. Four-weeks after the start of therapy with bromocriptine, the patient began to have regular menstrual cycles and became pregnant.

See references

Bromocriptine Breastfeeding Warnings

There are no data on the excretion of bromocriptine into human milk. Because bromocriptine suppresses lactation, bromocriptine is considered to be contraindicated during breast-feeding by the American Academy of Pediatrics.

See references

References for pregnancy information

  1. "Product Information. Parlodel (bromocriptine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  2. Murata Y, Ando H, Nagasaka T, et al. "Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma." J Clin Endocrinol Metab 88 (2003): 1988-93

References for breastfeeding information

  1. Committee on Drugs, 1992 to 1993 "The transfer of drugs and other chemicals into human milk." Pediatrics 93 (1994): 137-50

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.